Targeting DRP1 for breast cancer brain metastasis treatment
Exploring DRP1 as a target to inhibit metabolic reprogramming in dormant HER2+ breast cancer cells, potentially reducing brain metastasis by affecting mitochondrial plasticity and fatty acid oxidation.
Overview
This research focuses on the role of dynamin-related protein 1 (DRP1) in mitochondrial plasticity within dormant HER2+ breast cancer cells that have metastasized to the brain. The study suggests that DRP1-driven mitochondrial fission supports the survival of these cells by promoting fatty acid oxidation, metabolic reprogramming, and redox homeostasis. By targeting DRP1, either through depletion or pharmacological inhibition, it is possible to reduce fatty acid oxidation and increase lipid droplet accumulation, thereby impairing the survival of metastatic cells.
Technical specifications
- Target Protein: DRP1, responsible for mitochondrial fission.
- Mechanism: DRP1 inhibition reduces fatty acid oxidation and increases lipid droplet accumulation, affecting cell survival.
- Key Findings: Pharmacological inhibitor Midvi-1 reduces metastatic incidence in preclinical models.
- Future Work: Genetic engineering of DRP1 variants and metabolite tracing to further understand metabolic pathways and assess combination therapies.
Technology readiness level
This research is at Technology Readiness Level 4, indicating that the technology has been validated in laboratory settings but requires further development and validation in more complex models and clinical settings.
About University of Texas Southwestern Medical Center
UT Southwestern Medical Center is a leading academic medical center within the University of Texas System, combining biomedical research, education, and a major clinical enterprise in Dallas. Co-located hospitals and outpatient networks provide direct access to clinicians, diverse patient populations, and real‑world data, enabling rapid design and execution of clinical studies. Companies engage through on‑campus incubator space, shared core facilities, and collaboration models that range from sponsored research to multi‑site trials. Research is supported primarily by NIH, with additional competitive federal awards from other national agencies. A dedicated technology transfer office streamlines IP protection, licensing, and startup formation to accelerate commercialization.
delivered to your inbox.